Phase 2
N=30
The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Acute Infectious Conjunctivitis (Disorder)
Bottom Line
View on ClinicalTrials.gov: NCT05356793 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Complete Clinical Resolution — 9; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- SCH-1 (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Sacsh
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Clinical Resolution |
9; 0 | — |
Summary
The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.
Eligibility Criteria
Inclusion Criteria
- Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.
- At least 18 years of age.
- Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.
- Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.
- A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.
- All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.
- Patients will require a rating of 1 (mild) for bulbar conjunctival injection.
Exclusion Criteria
- Conjunctivitis greater than 72 hours after initial ocular symptoms
- Corneal ulcer, endophthalmitis, or any other confounding infection of the eye
- Patients taking topical anti-inflammatory medications on a chronic basis
- Known steroid glaucoma responders
- Active herpes ocular infection
- Pregnant women
- Known allergy to chlorhexidine
Data sourced from ClinicalTrials.gov (NCT05356793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.